Navigation Links
Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
Date:6/9/2009

SAN CARLOS, Calif., June 9 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the promotion of Lorianne Masuoka, M.D. to the position of Chief Medical Officer. Dr. Masuoka reports to Nektar's Senior Vice President, Drug Development and Chief Drug Development Officer, Randall Moreadith, M.D., Ph.D.

Dr. Masuoka has over 15 years of experience in clinical research and development. As Chief Medical Officer, she will be instrumental in helping to develop Nektar's clinical development strategy while continuing to oversee all clinical development functions, including Clinical Operations, Clinical Pharmacology, Drug Safety, Biometrics and Data Management. Dr. Masuoka joined Nektar in August 2008 as Vice President of Clinical Development.

"Lorianne's extensive clinical experience and superb guidance of our clinical development and operations teams make her an outstanding choice for Chief Medical Officer," said Randall Moreadith, M.D., Ph.D., Senior Vice President, Drug Development and Chief Drug Development Officer of Nektar, "Since joining Nektar, she has been instrumental in building our Drug Development group and assembling an internal Biometrics and Data Management Group, as well as streamlining our clinical operations."

Prior to Nektar, Lorianne was Vice President of Clinical Development at Five Prime Therapeutics where she led the advancement of a number of protein and antibody therapeutics in the areas of oncology, immunology and metabolic disease. Prior to that, Lorianne held senior leadership positions at Chiron and Berlex, where she was instrumental in development of Betaseron(R) for relapsing forms of multiple sclerosis as well as numerous oncology programs.

Dr. Masuoka received her M.D. from the University of California, Davis, completed a Fellowship
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Nektar Therapeutics Reports First Quarter 2009 Financial Results
2. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
3. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
4. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
5. Nektar Announces Retirement of Irwin Lerner from Board of Directors
6. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
7. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
8. Nektar Therapeutics to Webcast R&D Day on November 12th
9. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
10. Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City
11. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IPSWICH, England , January 15, 2014 ... to win races on the Formula 1 track could help ... between McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based ... funded by healthcare provider Simplyhealth. Telemetry technology, which ...
(Date:1/15/2014)... NY (PRWEB) January 15, 2014 The Microcompetition ... a major disease. One of these latent viruses is the ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory ... theory, a study found that RA patients have high concentrations ...
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, April ... Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... nonprofit organization solely dedicated to finding a cure for hepatitis ... worldwide, will host its annual Crystal Ball on Friday, April ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... Technology experts from over 20 countries are in ... environment, topics of global importance and immediacy. The ... forum to discuss initiatives in micromachining and nano ... economic and social outcomes. , The Summit promotes ...
... 6 Dendreon Corporation (Nasdaq: DNDN ) today reported ... for the first quarter of 2009 was $30,000 compared to $31,000 ... expenses for the three months ended March 31, 2009 were $17.0 ... The net loss for the quarter ended March 31, 2009 ...
... just six atoms thick in which electrons appear to ... their direction of travel has been discovered by a ... Working with computational models, the team has found that ... sandwiched between insulating sheets of titanium dioxide exhibit one ...
Cached Biology Technology:World Micromachine Summit highlights technologies impacting energy and the environment 2Dendreon Reports First Quarter 2009 Financial Results 2Dendreon Reports First Quarter 2009 Financial Results 3Dendreon Reports First Quarter 2009 Financial Results 4Dendreon Reports First Quarter 2009 Financial Results 5Nano-sandwich triggers novel electron behavior 2Nano-sandwich triggers novel electron behavior 3
(Date:4/23/2014)... have added "playwright" to their resumes in an effort ... onslaught of ethical issues as genomic science transitions to ... first sequenced. , Until now the plays of ... performed for, and by, their peers and others in ... classrooms. With Oxford University Press, publication of the ...
(Date:4/23/2014)... A new study from the Indiana University School of ... consumption and heart disease by finding a strong association ... deadly coronary heart disease. , The study found that ... disease by 57 percent, while no association was found ... non-meat sources, and coronary heart disease. , The study ...
(Date:4/23/2014)... Scarborough research shows that male black widow spiders prefer ... rare example of mate preference by male spiders. ... MacLeod and Maydianne Andrade, a professor in UTSC,s Department ... and the wild that males overwhelmingly chose to mate ... widows can tell whether a potential mate is well-fed ...
Breaking Biology News(10 mins):Bioethicists use theatrical narratives to bridge the gap between society and science 2Bioethicists use theatrical narratives to bridge the gap between society and science 3Study: Iron consumption can increase risk for heart disease 2Picky male black widow spiders prefer well-fed virgins 2
... team of scientists from the Johns Hopkins University ... method to accurately predict dengue fever outbreaks several ... method, known as PRedicting Infectious Disease Scalable Model ... socio-political data in Peru and in the Philippines. ...
... Neck, NY) The Brain & Behavior Research Foundation ... Schizophrenia and Depression) has announced approximately $4 million in ... close to $300 million in research to identify the ... illness. From about 500 applicants, forty research scientists ...
... Reportlinker.com announces that a new market research report ... Hand Geometry Industry http://www.reportlinker.com/p01139076/Global-Hand-Geometry-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Security_Systems ... in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ...
Cached Biology News:APL novel method accurately predicts disease outbreaks 2Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 2Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 3Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 4Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 5Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 6Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 7Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 8Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 9Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 10Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 11Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 12Global Hand Geometry Industry 2Global Hand Geometry Industry 3Global Hand Geometry Industry 4Global Hand Geometry Industry 5Global Hand Geometry Industry 6Global Hand Geometry Industry 7Global Hand Geometry Industry 8Global Hand Geometry Industry 9
2,4-Dinitrophenyl hapten is conjugated to BSA (Bovine Serum Albumin) protein through lysine....
4-Hydroxy-3-iodo-5-nitrophenylacetyl hapten is conjugated to BSA protein through lysine by amide bonds....
Amino Acid Analysis is performed using ion-exchange separation of the amino acids from acid hydrolysates, followed by ninhydrin detection. Typical quantities required are 0.1 to 0.5 mg, depending on...
2,4,6-Trinitrophenyl hapten is conjugated to Bovine Serum Albumin protein through lysine by amide bonds....
Biology Products: